Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
2020-01-01 Gentile, M; Morabito, F; Del Poeta, G; Mauro, Fr; Reda, G; Sportoletti, P; Laurenti, L; Coscia, M; Herishanu, Y; Recchia, Ag; Varettoni, M; Murru, R; Chiarenza, A; Condoluci, A; Moia, R; Pietrasanta, D; Loseto, G; Consoli, U; Scortechini, I; Rossi, Fm; Zucchetto, A; Fraticelli, V; Vigna, E; Botta, C; Tripepi, G; Arrigo, G; Rago, A; Angeletti, I; Biagi, A; Del Giudice, I; Bomben, R; Rigolin, Gm; Rossi, D; Di Raimondo, F; Gaidano, G; Polliack, A; Cuneo, A; Foà, R; Gattei, V.
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
2003-01-01 Mauro, Fr; Zinzani, P; Zaja, F; Gentile, M; Vegna, Ml; Stefoni, V; Marin, L; Fanin, R; Baccarani, M; Tura, S; Mandelli, F.
Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
2017-01-01 Molica, S; Giannarelli, D; Mirabelli, R; Levato, L; Gentile, M; Morabito, F; Montserrat, E.
More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia.
2010-01-01 Morabito, F; Cutrona, G; Gentile, M; Loiacono, F; Matis, S; Recchia, Ag; Gigliotti, V; Callea, V; Zupo, S; Ferrarini, M.
Janus kinase 2 inhibitors in myeloproliferative disorders.
2011-01-01 Lucia, E; Recchia, Ag; Gentile, M; Bossio, S; Vigna, E; Mazzone, C; Madeo, A; Morabito, L; Gigliotti, V; De Stefano, L; Caruso, N; Servillo, P; Franzese, S; Bisconte, Mg; Gentile, C; Morabito, F.
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
2020-01-01 Martino, M; Paviglianiti, A; Gentile, M; Martinelli, G; Cerchione, C.
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
2020-01-01 Merli, M; Luminari, S; Farina, L; Cocito, F; Defrancesco, I; Gini, G; Arcari, A; Scapinello, G; Gentile, M; Goldaniga, M; Loseto, G; Cencini, E; Greco, A; Molinari, Al; Ferrario, A; Bianchi, B; Mora, B; Bertù, L; Saturni, V; Bergamini, F; Fabbri, N; Rossi, Fg; Bolis, S; Passamonti, F; Arcaini, L.
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target
2015-01-01 Morabito, F; Gentile, M; Seymour, Jf; Polliack, A.
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety
2020-01-01 Martino, M; Naso, V; Porto, G; Paviglianiti, A; Ferreri, A; Loteta, B; Moscato, T; Console, G; Gentile, M; Rossi, M; Provenzano, Pf; Gori, M; Pitino, Al; Morabito, A; Tripepi, G.
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome
2016-01-01 Ronchetti, D; Manzoni, M; Agnelli, L; Vinci, C; Fabris, S; Cutrona, G; Matis, S; Colombo, M; Galletti, S; Taiana, E; Recchia, Ag; Bossio, S; Gentile, M; Musolino, C; Di Raimondo, F; Grilli, A; Bicciato, S; Cortelezzi, A; Tassone, P; Morabito, F; Ferrarini, M; Neri, A.
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
2016-01-01 Martino, M; Tripepi, G; Messina, G; Vincelli, Id; Console, G; Recchia, Ag; Gentile, M; Molica, S; Morabito, F.
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
2020-01-01 Goldman-Mazur, S; Jurczyszyn, A; Castillo, Jj; Waszczuk-Gajda, A; Grząśko, N; Radocha, J; Bittrich, M; Kortüm, Km; Gozzetti, A; Usnarska-Zubkiewicz, L; Valls, Jd; Jayabalan, Ds; Niesvizky, R; Kelman, J; Coriu, D; Rosiñol, L; Szukalski, Ł; González-Calle, V; Mateos, Mv; Jamroziak, K; Hus, I; Avivi, I; Cohen, Y; Mazur, P; Suska, A; Chappell, A; Madduri, D; Chhabra, S; Kleman, A; Hari, P; Delforge, M; Robak, P; Gentile, M; Kozłowska, I; Goldberg, Sl; Czepiel, J; Długosz-Danecka, M; Silbermann, R; Olszewski, Aj; Barth, P; Mikala, G; Chim, Cs; Vesole, Dh.
The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis.
2013-01-01 Molica, S; Giannarelli, D; Gentile, M; Cutrona, G; Di Renzo, N; Di Raimondo, F; Neri, A; Federico, M; Ferrarini, M; Morabito, F.
Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium.
2012-01-01 Morabito, F; Recchia, Ag; Mazzone, C; Gentile, M
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens
2011-01-01 Benevolo, G; Larocca, A; Gentile, M; Pregno, P; Gay, F; Botto, B; Frairia, C; Evangelista, A; Morabito, F; Boccadoro, M; Vitolo, U; Palumbo, A.
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases.
2018-01-01 Morabito, F; Shanafelt, Td; Gentile, M; Reda, G; Mauro, Fr; Rossi, D; Di Renzo, N; Molica, S; Angrilli, F; Chiarenza, A; Cutrona, G; Chaffee, Kg; Parikh, Sa; Tripepi, G; D'Arrigo, G; Vigna, E; Recchia, Ag; Cortelezzi, A; Gaidano, G; Di Raimondo, F; Fais, F; Foà, R; Neri, A; Ferrarini, M.
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression
2020-01-01 Tissino, E; Pozzo, F; Benedetti, D; Caldana, C; Bittolo, T; Rossi, Fm; Bomben, R; Nanni, P; Chivilò, H; Cattarossi, I; Zaina, E; Norris, K; Polesel, J; Gentile, M; Tripepi, G; Moia, R; Santinelli, E; Innocenti, I; Olivieri, J; D'Arena, G; Laurenti, L; Zaja, F; Pozzato, G; Chiarenza, A; Di Raimondo, F; Rossi, D; Pepper, C; Hartmann, Tn; Gaidano, G; Del Poeta, G; Gattei, V; Zucchetto, A.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
2018-01-01 Breccia, M; Abruzzese, E; Castagnetti, F; Bonifacio, M; Gangemi, D; Sorà, F; Iurlo, A; Luciano, L; Gozzini, A; Gentile, M; Bocchia, M; Luzi, D; Maggi, A; Sgherza, N; Isidori, A; Crugnola, M; Pregno, P; Scortechini, Ar; Capodanno, I; Pizzuti, M; Foà, R.
Do Biologic Parameters Affect the Time to First Treatment of Clinical Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia Rai Stage 0? Results of a Prospective Analysis
2014-01-01 Molica, S; Giannarelli, D; Levato, L; Gentile, M; Mirabelli, R; Morabito, F.
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases
2014-01-01 Gentile, M; Mauro, Fr; Rossi, D; Vincelli, I; Tripepi, G; Recchia, Ag; De Stefano, L; Campanelli, M; Giannarelli, D; Bossio, S; Morabito, L; Vigna, E; Gaidano, G; Foà, R; Morabito, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study | 1-gen-2020 | Gentile, M; Morabito, F; Del Poeta, G; Mauro, Fr; Reda, G; Sportoletti, P; Laurenti, L; Coscia, M; Herishanu, Y; Recchia, Ag; Varettoni, M; Murru, R; Chiarenza, A; Condoluci, A; Moia, R; Pietrasanta, D; Loseto, G; Consoli, U; Scortechini, I; Rossi, Fm; Zucchetto, A; Fraticelli, V; Vigna, E; Botta, C; Tripepi, G; Arrigo, G; Rago, A; Angeletti, I; Biagi, A; Del Giudice, I; Bomben, R; Rigolin, Gm; Rossi, D; Di Raimondo, F; Gaidano, G; Polliack, A; Cuneo, A; Foà, R; Gattei, V. | |
| Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. | 1-gen-2003 | Mauro, Fr; Zinzani, P; Zaja, F; Gentile, M; Vegna, Ml; Stefoni, V; Marin, L; Fanin, R; Baccarani, M; Tura, S; Mandelli, F. | |
| Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. | 1-gen-2017 | Molica, S; Giannarelli, D; Mirabelli, R; Levato, L; Gentile, M; Morabito, F; Montserrat, E. | |
| More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. | 1-gen-2010 | Morabito, F; Cutrona, G; Gentile, M; Loiacono, F; Matis, S; Recchia, Ag; Gigliotti, V; Callea, V; Zupo, S; Ferrarini, M. | |
| Janus kinase 2 inhibitors in myeloproliferative disorders. | 1-gen-2011 | Lucia, E; Recchia, Ag; Gentile, M; Bossio, S; Vigna, E; Mazzone, C; Madeo, A; Morabito, L; Gigliotti, V; De Stefano, L; Caruso, N; Servillo, P; Franzese, S; Bisconte, Mg; Gentile, C; Morabito, F. | |
| Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? | 1-gen-2020 | Martino, M; Paviglianiti, A; Gentile, M; Martinelli, G; Cerchione, C. | |
| Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. | 1-gen-2020 | Merli, M; Luminari, S; Farina, L; Cocito, F; Defrancesco, I; Gini, G; Arcari, A; Scapinello, G; Gentile, M; Goldaniga, M; Loseto, G; Cencini, E; Greco, A; Molinari, Al; Ferrario, A; Bianchi, B; Mora, B; Bertù, L; Saturni, V; Bergamini, F; Fabbri, N; Rossi, Fg; Bolis, S; Passamonti, F; Arcaini, L. | |
| Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target | 1-gen-2015 | Morabito, F; Gentile, M; Seymour, Jf; Polliack, A. | |
| Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety | 1-gen-2020 | Martino, M; Naso, V; Porto, G; Paviglianiti, A; Ferreri, A; Loteta, B; Moscato, T; Console, G; Gentile, M; Rossi, M; Provenzano, Pf; Gori, M; Pitino, Al; Morabito, A; Tripepi, G. | |
| lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome | 1-gen-2016 | Ronchetti, D; Manzoni, M; Agnelli, L; Vinci, C; Fabris, S; Cutrona, G; Matis, S; Colombo, M; Galletti, S; Taiana, E; Recchia, Ag; Bossio, S; Gentile, M; Musolino, C; Di Raimondo, F; Grilli, A; Bicciato, S; Cortelezzi, A; Tassone, P; Morabito, F; Ferrarini, M; Neri, A. | |
| A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy | 1-gen-2016 | Martino, M; Tripepi, G; Messina, G; Vincelli, Id; Console, G; Recchia, Ag; Gentile, M; Molica, S; Morabito, F. | |
| Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients | 1-gen-2020 | Goldman-Mazur, S; Jurczyszyn, A; Castillo, Jj; Waszczuk-Gajda, A; Grząśko, N; Radocha, J; Bittrich, M; Kortüm, Km; Gozzetti, A; Usnarska-Zubkiewicz, L; Valls, Jd; Jayabalan, Ds; Niesvizky, R; Kelman, J; Coriu, D; Rosiñol, L; Szukalski, Ł; González-Calle, V; Mateos, Mv; Jamroziak, K; Hus, I; Avivi, I; Cohen, Y; Mazur, P; Suska, A; Chappell, A; Madduri, D; Chhabra, S; Kleman, A; Hari, P; Delforge, M; Robak, P; Gentile, M; Kozłowska, I; Goldberg, Sl; Czepiel, J; Długosz-Danecka, M; Silbermann, R; Olszewski, Aj; Barth, P; Mikala, G; Chim, Cs; Vesole, Dh. | |
| The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. | 1-gen-2013 | Molica, S; Giannarelli, D; Gentile, M; Cutrona, G; Di Renzo, N; Di Raimondo, F; Neri, A; Federico, M; Ferrarini, M; Morabito, F. | |
| Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium. | 1-gen-2012 | Morabito, F; Recchia, Ag; Mazzone, C; Gentile, M | |
| The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens | 1-gen-2011 | Benevolo, G; Larocca, A; Gentile, M; Pregno, P; Gay, F; Botto, B; Frairia, C; Evangelista, A; Morabito, F; Boccadoro, M; Vitolo, U; Palumbo, A. | |
| Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases. | 1-gen-2018 | Morabito, F; Shanafelt, Td; Gentile, M; Reda, G; Mauro, Fr; Rossi, D; Di Renzo, N; Molica, S; Angrilli, F; Chiarenza, A; Cutrona, G; Chaffee, Kg; Parikh, Sa; Tripepi, G; D'Arrigo, G; Vigna, E; Recchia, Ag; Cortelezzi, A; Gaidano, G; Di Raimondo, F; Fais, F; Foà, R; Neri, A; Ferrarini, M. | |
| CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression | 1-gen-2020 | Tissino, E; Pozzo, F; Benedetti, D; Caldana, C; Bittolo, T; Rossi, Fm; Bomben, R; Nanni, P; Chivilò, H; Cattarossi, I; Zaina, E; Norris, K; Polesel, J; Gentile, M; Tripepi, G; Moia, R; Santinelli, E; Innocenti, I; Olivieri, J; D'Arena, G; Laurenti, L; Zaja, F; Pozzato, G; Chiarenza, A; Di Raimondo, F; Rossi, D; Pepper, C; Hartmann, Tn; Gaidano, G; Del Poeta, G; Gattei, V; Zucchetto, A. | |
| Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. | 1-gen-2018 | Breccia, M; Abruzzese, E; Castagnetti, F; Bonifacio, M; Gangemi, D; Sorà, F; Iurlo, A; Luciano, L; Gozzini, A; Gentile, M; Bocchia, M; Luzi, D; Maggi, A; Sgherza, N; Isidori, A; Crugnola, M; Pregno, P; Scortechini, Ar; Capodanno, I; Pizzuti, M; Foà, R. | |
| Do Biologic Parameters Affect the Time to First Treatment of Clinical Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia Rai Stage 0? Results of a Prospective Analysis | 1-gen-2014 | Molica, S; Giannarelli, D; Levato, L; Gentile, M; Mirabelli, R; Morabito, F. | |
| Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases | 1-gen-2014 | Gentile, M; Mauro, Fr; Rossi, D; Vincelli, I; Tripepi, G; Recchia, Ag; De Stefano, L; Campanelli, M; Giannarelli, D; Bossio, S; Morabito, L; Vigna, E; Gaidano, G; Foà, R; Morabito, F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista40395
- 2 Contributo in Volume2
Data di pubblicazione
- In corso di stampa37
- 2020 - 202713197
- 2010 - 201915036
- 2000 - 20097892
- 1990 - 19993088
- 1980 - 19891038
- 1971 - 1979109
Editore
- Society for information display2
- TAYLOR & FRANCIS LTD, 4 PARK SQUA...2
- "Il pensiero scientifico" Editore1
- American Physical Society1
- Athens Institute for Education an...1
- Deputazione Storia Patria per la ...1
- Edizioni Scientifiche Calabresi1
- ELSEVIER SCIENCE BV, PO BOX 211, ...1
- ETS1
- Geological Society of America Spe...1
Rivista
- JOURNAL OF HIGH ENERGY PHYSICS498
- PHYSICS LETTERS. SECTION B469
- THE EUROPEAN PHYSICAL JOURNAL. C,...397
- PHYSICAL REVIEW LETTERS272
- MOLECULES176
- PHYSICAL REVIEW D173
- BOLLETTINO FILOSOFICO168
- INTERNATIONAL JOURNAL OF MOLECULA...166
- APPLIED SCIENCES164
- FILOLOGIA ANTICA E MODERNA151
Serie
- ATINER'S CONFERENCE PAPER SERIES1
- INTERNATIONAL REVIEW OF NEUROBIOLOGY1
Keyword
- Humans268
- COVID-19164
- Italy154
- Calabria113
- Hadron-Hadron Scattering111
- Female110
- High Energy Physics - Experiment106
- Palladium105
- Hadron-Hadron scattering (experim...95
- Carbonylation88
Lingua
- eng28606
- ita6840
- fre287
- spa245
- ger96
- grc23
- alb18
- por16
- tur12
- lat10
Accesso al fulltext
- no fulltext39868
- open457
- reserved44
- restricted21
- internalNetwork5
- embargoed1
- partially open1